State Street Global Advisors Reports Dealings in Avadel Pharmaceuticals plc (AVDL)
On January 5, 2026, State Street Global Advisors & Affiliates disclosed significant dealings in Avadel Pharmaceuticals plc (AVDL), as mandated by Rule 8.3 of the Irish Takeover Panel Act of 1997. This report highlights transactions that fall under the category of relevant securities, where State Street has demonstrated a keen interest in the pharmaceutical sector.
Key Transaction Details
- Date of Dealing: January 5, 2026
- Company: Avadel Pharmaceuticals plc
- Class of Relevant Security: $0.01 ordinary shares
Interests and Positions in AVDL Securities
Following the recent dealings, State Street Global Advisors reported the following long and short positions in Avadel Pharmaceuticals:
- Relevant Securities: 2,289,115 shares (2.35014% of total)
- Derivatives (other than options): N/A
- Options and Agreements to Purchase/Sell: N/A
This continued holding reflects the firm's confidence in Avadel's market prospects.
Recent Dealings Summary
State Street Global Advisors engaged in multiple securities transactions impacting AVDL's stock. Here’s a summary of their purchases and sales:
- Purchases:
- 6,600 shares at $21.50 each
- 4,100 shares at $21.49 each
- 4,868 shares at $21.50 each
- Sales:
- 7,302 shares at $21.50 each
These transactions underscore State Street's strategic positioning in relation to Avadel Pharmaceuticals.
Other Relevant Information
State Street has not disclosed any agreements or arrangements regarding options or derivatives in relation to AVDL securities. As of the disclosure date, there are no supplementary forms attached. The contact person for this report is Divya K, reachable at +918067452364.